Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

Chng, W-J; Goldschmidt, H.; Dimopoulos, M. A.; Moreau, P.; Joshua, D.; Palumbo, A.; Facon, T.; Ludwig, H.; Pour, L.; Niesvizky, R.; Oriol, A.; Rosinol, L.; Suvorov, A.; Gaidano, G.; Pika, T.; Weisel, K.; Goranova-Marinova, V.; Gillenwater, H. H.; Mohamed, N.; Feng, S.; Aggarwal, S.; Hajek, R.

dc.contributor.author	Weisel, Katja
dc.date.accessioned	2017-08-30T15:00:55Z
dc.date.available	2017-08-30T15:00:55Z
dc.date.issued	2017
dc.identifier.issn	1476-5551
dc.identifier.uri	http://hdl.handle.net/10900/77646
dc.language.iso	en	en
dc.publisher	Nature Publishing Group	de_DE
dc.relation.uri	http://dx.doi.org/10.1038/leu.2016.390	de_DE
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.ddc	610	de_DE
dc.title	Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR	de_DE
dc.type	Article	de_DE
utue.quellen.id	20170815222223_00618
utue.publikation.seiten	1368-1374	de_DE
utue.personen.roh	Chng, W-J
utue.personen.roh	Goldschmidt, H.
utue.personen.roh	Dimopoulos, M. A.
utue.personen.roh	Moreau, P.
utue.personen.roh	Joshua, D.
utue.personen.roh	Palumbo, A.
utue.personen.roh	Facon, T.
utue.personen.roh	Ludwig, H.
utue.personen.roh	Pour, L.
utue.personen.roh	Niesvizky, R.
utue.personen.roh	Oriol, A.
utue.personen.roh	Rosinol, L.
utue.personen.roh	Suvorov, A.
utue.personen.roh	Gaidano, G.
utue.personen.roh	Pika, T.
utue.personen.roh	Weisel, K.
utue.personen.roh	Goranova-Marinova, V.
utue.personen.roh	Gillenwater, H. H.
utue.personen.roh	Mohamed, N.
utue.personen.roh	Feng, S.
utue.personen.roh	Aggarwal, S.
utue.personen.roh	Hajek, R.
dcterms.isPartOf.ZSTitelID	Leukemia	de_DE
dcterms.isPartOf.ZS-Issue	6	de_DE
dcterms.isPartOf.ZS-Volume	31	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE